PR in the Philippines

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics"ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."CIL's global manufacturing network, including facilities in North America, Europe, and Asia, enables CIL to provide a diversified and resilient supply chain for pharmaceutical partners. Every ISOAPI-D product is manufactured in ISO 9001-certified facilities, ensuring the highest standards of quality, regulatory compliance, and full traceability throughout the production process.A core component of the ISOAPI-D line is heavy water (D₂O), which is sourced exclusively from approved suppliers. This product is fully traceable and tritium-free, aligning with stringent safety and regulatory requirements of the pharmaceutical industry.The ISOAPI-D range also features advanced intermediates that allow for more streamlined synthetic pathways. By reducing the number of synthesis steps and optimizing production efficiency, these intermediates can help lower manufacturing costs and accelerate the time to market for new therapeutics.Since 1981, CIL has been a trusted supplier of premium deuterated materials to leading pharmaceutical and biotechnology companies worldwide. This longstanding commitment to quality and reliability continues with the launch of ISOAPI-D, offering customers a secure, high-quality supply of essential reagents and reducing operational risk in their development pipelines."ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation," said Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL. "Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."Visit CIL at CPhI Frankfurt, Stand #2.0G2, October 28-30, to discover ISOAPI-D, the future of deuterated chemistry for pharmaceuticals.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds.Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA AND HYDERABAD, INDIA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India's Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.Cliff Caldwell, CEO at CIL noted, "We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries."Vishal Rajput, CEO of CCS said, "The collaboration and newly formed entity will leverage CCS's strong infrastructure and deep technical capabilities in India, while integrating CIL's world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities." Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.About Chemtatva Chiral Solutions, Pvt. Ltd.CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Japan, October 27, 2025 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (Honda) today announced its decision to invest in OMC Power Private Limited (OMC Power), which conducts distributed power supply and mini-grid business in India. The aim of the investment is to contribute to stable power supply utilizing batteries, which is expected to expand in line with the accelerating electrification of mobility products in India. In January 2026, OMC Power will launch a leasing business for uninterruptible power supply (UPS) device using the Honda Mobile Power Pack e: portable and swappable battery.India has the world’s largest population and rapid economic growth, yet some of its regions demand access to a stable supply of electricity. For those areas requiring stable power supply, diesel generators are widely used as one of the emergency backup power sources, raising growing concerns over health risks from exhaust emissions. To address such societal challenges, jointly with OMC Power, Honda has been conducting demonstration testing of the UPS device using Honda Mobile Power Pack e: in the state of Uttar Pradesh in northern India since 2023. This initiative has confirmed that secondary use as in repurposing of batteries of electric motorcycles can contribute to stable energy supply as well as reduced environmental impact to the region. Based on the result of this testing, Honda has decided to invest in OMC Power to further facilitate the repurposing of batteries.  For the leasing business, Honda Power Pack Energy India Pvt. Ltd. (HEID), a Honda subsidiary in India conducting a battery sharing service, will supply OMC Power with the Honda Mobile Power Pack e:. Then OMC Power will package Honda Mobile Power Pack e: with its UPS device and offer it for lease sales to households, small businesses and schools and other facilities.With this UPS device, the battery will be charged with grid electricity when available, then the charged battery will supply electricity when the grid power is unstable or down, enabling customers to use electricity more stably without interruption. Uninterruptible power supply (UPS) device equippedwith Honda Mobile Power Pack e:Comments by Minoru Kato, Chief Officer for Motorcycle and Power Products Operations, Head of Motorcycle Business Unit, and Executive Officer of Honda Motor Co., Ltd.“Honda believes that electrified mobility products can contribute not only as a means of transportation but also to the advancement of energy systems for our customers and their local communities. In India, where the shift toward electric motorcycles is progressing, Honda will strive to establish a resource-circulating value chain by facilitating the repurposing of end-of-life electric motorcycle batteries. Through this initiative, with a comprehensive approach from the perspective of both our products and business activities, Honda will contribute to addressing societal issues and making people’s daily lives more enjoyable.”Comments by Rohit Chandra, Co-Founder & CEO, OMC Power Private Limited “This partnership with Honda marks a pivotal moment in OMC’s journey. Together, we are unlocking a new era of sustainable innovation by integrating innovative energy storage solutions into our distributed energy systems. This model reflects the vision of Make in India and Aatma Nirbhar Bharat, driving local innovation, strengthening energy security, and enabling inclusive growth. By combining global expertise with India’s entrepreneurial spirit, we are building scalable solutions that will shape the future of storage based clean energy solutions.”  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life today announced the signing of a Memorandum of Understanding with Gleneagles Hospital Hong Kong (“Gleneagles”), CUHK Medical Centre (“CUHKMC”), and Hong Kong Baptist Hospital (“HKBH”) to establish strategic partnerships. In a pioneering move, CTF Life has also become the first insurance company to collaborate with Gleneagles MediCentre in Admiralty to launch an exclusive programme to provide customers with health management solutions. At the same time, the PrimeChamp Doctor Network has been enhanced with the official inclusion of the three hospitals and their affiliated medical centres. This expanded medical network now spans across Hong Kong, offering customers priority referrals, appointment scheduling and direct billing services.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “We are pleased to forge long-term business partnerships with three leading and distinguished hospitals. Harnessing the strengths of the Chow Tai Fook Group ecosystem, we are committed to providing our customers with more flexible and superior medical service solutions, serving as their Life Planner. This collaboration not only further solidifies our medical network across Hong Kong, but also elevates the overall service experience at CTF Life, empowering customers with greater autonomy, convenience and comprehensive medical service experiences at every stage of their life journey. We firmly believe that medical protection should go beyond claims, it should accompany our customers across every stage from prevention and diagnosis to treatment and recovery, truly bringing to life our vision of creating value beyond healthcare.”Territory-wide Medical Network Coverage Across Hong KongThe three hospitals will respectively serve as CTF Life’s designated medical network partners on Hong Kong Island, Kowloon, and the New Territories. Their doctors and mental health therapists will also join the PrimeChamp Doctor Network, providing customers with convenient, high-quality, and comprehensive medical services.Hong Kong Island: Gleneagles Hospital Hong KongGleneagles serves as the appointed medical network partner for Hong Kong Island. CTF Life has also become the first insurance company to collaborate with the newly opened Gleneagles MediCentre in Admiralty, further expanding its service scope through exclusive programmes. These programmes include gastroscopy, colonoscopy and wart removal services, providing customers with prevention-oriented health management solutions.New Territories: CUHK Medical CentreCUHKMC will serve as the selected medical network partner for the New Territories. Backed by a top-tier medical team comprising professors from the CUHK Faculty of Medicine and specialists, coupled with advanced medical facilities and strong research capabilities, CUHKMC provides customers with premium, multi-specialty medical services. Dedicated to translating cutting-edge international medical research into clinical practice, CUHKMC delivers a world-class diagnostic and treatment experience that benefits both customers and the wider community.Kowloon: Hong Kong Baptist HospitalHKBH will serve as the designated medical network partner for Kowloon.  Operating under a “One Hospital, Multiple Service Sites” synergy model, the hospital enables patients to conveniently access medical services close to their preferred location. Among these sites, the HKBH East Kowloon Medical Centre (EKMC), located in the Kwun Tong Business District (Ngau Tau Kok), provides pre-approved direct billing services for cataract surgery and oncology treatments. Additionally, mental health team offers professional guidance to help individuals better understand and manage their psychological well-being. Together, these services embrace the Hospital mission: “In the Service of Man, for the Glory of God.”Customer-Exclusive Medical Services Reflects a People-Centric ApproachThrough this collaboration, the three hospitals will offer the following services for CTF Life customers:- Priority referral and appointment scheduling, significantly reducing waiting time.- Direct billing services, allowing customers to receive treatment without upfront payment, easing financial pressure.- One-stop cancer treatment services, covering diagnosis, treatment, and post-surgery rehabilitation, providing comprehensive support throughout the care journey.- Access to premium medical services and coordination, arranging professor-level doctors and advanced medical facilities to ensure customers receive the highest quality of medical care.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.Media enquiriesCTF LifeCorporate Communications DepartmentVecinia Lau+852 2591 8297vecinia.lau@ctflife.com.hk Chow Tai Fook Life Insurance Company Limited (Incorporated in Bermuda with limited liability) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 27th Hong Kong International Lighting Fair (Autumn Edition) opened today and will run for four days, and the 10th Hong Kong International Outdoor and Tech Light Expo will open tomorrow. The twin lighting fairs bring together some 3,000 exhibitors from 20 countries and regions.- The returning Innovative Lighting Design Forum held today features case studies and global market insights.- Renowned lighting designer Tino Kwan will host a masterclass tomorrow (28 October) at HKCEC titled “The Language of Light: From Artistic Design to Everyday Experience.”- Several exhibitors set up immersive experience zones, to enable visitors to explore product trends in human-centric lighting, artificial intelligence, and the silver market.HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – The 27th Hong Kong International Lighting Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), opened today and will run for four days until 30 October at the Hong Kong Convention and Exhibition Centre, while the 10th Hong Kong International Outdoor and Tech Light Expo will take place from 28 to 31 October at AsiaWorld-Expo.Deputy Executive Director of the HKTDC Jenny Koo said: "The development of innovative lighting products is thriving, with significant growth potential. Under the theme “Illuminated Designs for a Smarter Future”, the twin lighting fairs showcase innovative products and smart lighting solutions from some 3,000 exhibitors across 20 countries and regions. The fairs are highly international, in addition to exhibitors from Hong Kong, the Chinese Mainland and Taiwan, we also welcome exhibitors from Denmark, Finland, Germany, the Netherlands, the United Kingdom and the United States.”Centred on innovation and smart design, the Hall of Connected Lighting, which was upgraded last year, returns as the event’s focal point. The hall features some 70 leading brands, with an increase in the number of brands, countries and regions represented. In addition to showcasing a wide range of innovative smart lighting products and solutions, the hall also features several specially designed experience zones, showcasing meticulously designed scenarios, cutting-edge applications, and technologies. In the experience zone, visitors will be immersed in a multi-dimensional light installation that fuses art and technology, and experience a hands-on encounter with AI integrated applications in health and wellness, as well as innovative solutions for the silver market. The Hall of Connected Lighting features renowned brands such as Casambi from Finland, Moorgen from Germany, Signify from the Netherlands, and Koizumi from Japan, showcasing award-winning designs, designer collections, and lamps and lighting solutions used in iconic projects around the world. Major industry alliances playing key roles in the fields of smart lighting and the Internet of Things are gathered at the fair, including the DALI Alliance and SILA-EMN Alliance, as well as new participants this year such as the Connectivity Standards Alliance and the Zhaga Consortium, collectively presenting the full spectrum of the smart lighting ecosystem. They bring together member enterprises from around the world, including Elite Intelligence, Broadlink and Inventronics from the Chinese Mainland, LEDiL from Finland, France’s Nicolaudie, and Germany’s CUPOWER to showcase the smart lighting ecosystem.Another highlight is the Hall of Aurora, which brings together some 540 renowned brands offering high-quality lighting products. They include Prosperity Group and General Lighting from Hong Kong, LEEDARSON, Tospo and Je Woo from the Chinese Mainland, Lival from Finland and Megaman from Germany. Other featured zones include Commercial Lighting, LED Essentials, LED Lighting, Residential Lighting and Testing, Certification & Inspection, providing buyers with one-stop sourcing opportunities.The Hong Kong International Outdoor and Tech Light Expo showcases a diverse range of outdoor commercial and industrial lighting solutions, enabling the development of smart cities. The Smart Pole and Solution Zone, introduced last year, will return to showcase innovative solutions that aid in enhancing the quality of life and energy efficiency optimisation. E-Lite Semiconductor Inc. showcases its smart light poles, equipped with energy-efficient LED lighting and Environmental Sensing technology. These poles monitor air quality, temperature, humidity, and noise levels, and assist with real-time traffic monitoring when integrated with traffic cameras and sensors. Furthermore, Shenzhen Zhongchuang Lighting Technology presents its patented modular square stadium lights in the Technical & Professional Lighting zone. Engineered for functionality, the product allows for individual module replacement in the event of damage – greatly simplifying installation and maintenance while reducing operational costs. The Horticultural Lighting zone showcases advanced horticultural lighting technologies and multifunctional lamps suitable for outdoor parks and home gardens. The Outdoor and Public Lighting zone continues to showcase lamps designed for outdoor public spaces and advertising.Twin fairs focus on multiple lighting trendsImmersive smart lighting experience and design master series   Smart homes are becoming increasingly popular. According to Statista, smart lighting is projected to become a massive $44 billion market by 2030, allowing users to adjust brightness, colour and temperature as needed. Exhibitors at this year's Autumn Lighting Fair have also thoughtfully designed various settings to offer buyers hands-on experiences. For example, Casambi has created the Artisan Café, a boutique coffee space illuminated in collaboration with ERCO, a globally acclaimed architectural and commercial lighting brand. Combining digital lighting systems with on-site ambiance, the café offers attendees a unique and immersive experience to connect and exchange ideas while enjoying their coffee. The lighting is configured to simulate natural light at different times of the day, featuring four distinct scenario demonstrations. TUYA Smart has constructed scenes such as living room and a bedroom to demonstrate how lighting and AI technologies can be integrated into smart lighting solutions. Moorgen also presents several cross-over collections from global design masters, including smart lamps designed in collaboration with two receivers of the DFA World’s Outstanding Chinese Designer Award, Chi-wing Lo and Tino Kwan; acclaimed Hong Kong architect, interior and product designer Steve Leung; Spanish designer Jorge Herrera; and internationally renowned design studio Yabu Pushelberg. Among the innovations on show, the Flower of Paris Motorised Track Light makes its global debut at the Autumn Lighting Fair and features a design collaboration with Ma Yansong – the first architect from the Chinese Mainland to win the right to design an international landmark building. As the result of two years’ development, the track light features a 355-degree rotating head and adjustable beam angles of 10, 15 and 25 degrees, flexibly illuminating every detail. Equipped with an intelligent control system, the track light can be operated remotely with effortless scene switches. Architectural lighting fixtures designed by Tino Kwan also makes a Hong Kong debut.Lighting and health are interdependent   "Human-centric lighting" will continue to be a key focus in 2025. From lighting solutions that align with circadian rhythms to antibacterial UV-C technology, lighting is becoming a tool for enhancing health. Signify unveils its VitaUp Vitamin D3 Modules by Philips at the fair, offering a safe, controlled source of low-intensity UVB exposure to naturally support healthy vitamin D levels. Designed for long-term and low-intensity use, five-days of exposure delivers the equivalent UVB dose of a 15-minute midday walk two to three times per week in spring or summer. Another highlight is that Jiangsu Insona Communication Technology Co.  also brings a smart lighting system that uses a circadian algorithm synchronised with local sunrise and sunset times without requiring network connectivity, thereby supporting the body’s natural biological rhythm. Foshan Electrical and Lighting Co. also sets up an experience zone to launch its Eye-care Ceiling Light, specially designed to meet the needs of the silver market. Tailored for elderly people, the light improves visual clarity by 15%, supports circadian rhythm and boosts lighting efficiency by 12%, reducing eye fatigue.Award-winning designs and global landmark lighting showcased at the twin fairs  According to a lighting industry survey conducted by the HKTDC in April, 37% of respondents believe LED lighting has the greatest growth potential. A wide array of LED-innovations are on display, including the Filmbase flying screen developed by Filmbase Tech, a national-level high-tech and Specialised, Refined, Distinctive and Innovative enterprise. This ground-breaking product has set a new Guinness World Record as the world’s largest LED mesh mid-air suspended screen. Hong Kong’s GRE Alpha brings LED drivers and light strings that were used in the lighting show and horticultural system at Gardens by the Bay in Singapore. General Lighting Innovation showcases its Neon Strip which is renowned for its exceptional flexibility, impact resistance and all-weather durability. The latest models allow custom cutting and instant connection on site, enabling versatile installation to suit various spatial designs and creative lighting applications. At the Hong Kong International Outdoor and Tech Light Expo, AGC Lighting Co showcases several outdoor lighting fixtures that have won the German IF Design Award and the Red Dot Design Concept Award. Among them, the UFO High Bay Light features a unique design, enhanced by precision optics and high-efficiency power components. Its integrated system allows for both power and correlated colour temperature (CCT) adjustments in the one fixture.Experts discuss market trendsThe Innovative Lighting Design Forum held today (27 October) at the HKCEC explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Speakers included representatives from celebrated international and local companies, as well as architects and lighting designers, who shared top design cases from various regions and analysed market trends. Tomorrow (28 October), the Connected Lighting Forum will delve into smart living ecosystems and sustainable lighting development. It will also feature the launch ceremony for “Edge Mixed Networking (EMN) Technical Requirements for Smart Buildings”. On the same afternoon, renowned lighting designer Tino Kwan will host a masterclass titled “The Language of Light: From Artistic Design to Everyday Experience” and share design principles for enhancing daily life through light and the impact of light on mood, functionality and spatial characteristics. Additionally, a seminar titled “Illuminating the Cycle: Outdoor Lighting Designs for a Sustainable Future” will be held tomorrow (28 October) at AsiaWorld-Expo, focusing on how outdoor lighting can integrate sustainability concepts.Running concurrently from 28 to 31 October, the Outdoor and Tech Light Expo and Eco Expo Asia at AsiaWorld-Expo, alongside the Autumn Lighting Fair at the Hong Kong Convention and Exhibition Centre (HKCEC), present a dynamic platform for cross-sector business opportunities. Free shuttle bus services will be provided between the HKCEC and AsiaWorld-Expo from 28 to 30 October.Under the EXHIBITION+ hybrid model, exhibitors and buyers can meet online through the Click2Match business matching platform in addition to attending the physical fair. The online fairs run from 20 October to 7 November, facilitating business expansion both online and offline. 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition)10th HKTDC Hong Kong International Outdoor and Tech Light ExpoDate27-30 Oct 2025 (Monday to Thursday)28-31 Oct 2025 (Tuesday to Friday)Opening hours27-29 Oct 2025: 9:30am-7pm30 Oct 2025: 9:30am-4pm28 Oct 2025: 10:30am-6pm29-30 Oct 2025: 10am-6pm31 Oct 2025: 10am-5pmVenueHong Kong Convention and Exhibition CentreAsiaWorld-ExpoPress Registration CounterHall 1C Concourse, HKCEC, or at the HKTDC Media Centre (G/F, HKCEC, 1 Expo Drive, Wan Chai)AsiaWorld-Expo East LobbyMedia CentreHKTDC Media CentreRoom 108, Hall 8 Side Entrance, AsiaWorld-ExpoFair websitehklightingfairae.hktdc.com/tchkotlexpo.hktdc.comPhoto download: http://bit.ly/43F182CThe 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition) opens today, showcasing a wide variety of smart lighting products and solutions.The Hall of Connected Lighting returns, showcasing designs and smart technologies from prominent companies and brands.Under the theme ‘Illuminated Designs for a Smarter Future’, exhibitors at the twin lighting fairs present multiple experiential zones featuring meticulously designed lighting scenes, cutting-edge applications, and technologies, allowing visitors to immerse themselves in a multi-dimensional light and shadow experience at the intersection of art and technology.The Hall of Aurora brings together some 540 notable brands offering high-quality lighting products and technologies.The Innovative Lighting Design Forum took place today and explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Representatives from celebrated international and local companies, as well as architects and lighting designers, shared design works from various regions and analysed market trends.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Terrapinn announces the 10th anniversary edition of EDUtech Asia, Asia’s largest and most influential education event, taking place on 5 - 6 November 2025 at Sands Expo & Convention Centre, Singapore. Under the theme “Positive disruption: unlocking limitless potential in education with AI and tech,” the event will bring together more than 8,000 education leaders, policymakers and technology innovators to explore how AI is transforming learning while ensuring that human connection, purpose and equity remain at the heart of education.Global Visionaries Lead the AI ConversationThis year’s keynote lineup features some of the most influential voices in global education. Professor Pasi Sahlberg(University of Melbourne) will examine why many schools remain “tech-rich but transformation-poor” and what must change to unlock AI’s true impact on learning and equity. Dr Yuhyun Park, creator of the Digital Intelligence (DQ) Framework, will reveal how education systems can rapidly build AI literacy and empower every learner to thrive in an AI-driven world. Graham Brown-Martin, renowned futurist and Founder of Learning Without Frontiers, will explore how AI, immersive technologies and human skills are converging to shape a new global learning ecosystem. A major highlight will be the live keynote debate featuring Professor Pasi Sahlberg and Associate Professor Dr Ng Pak Tee (National Institute of Education, Singapore), who will confront one of the most important questions facing global education: Can AI ever replicate the human heart of teaching, or is the future of learning defined by a powerful partnership between human and machine intelligence?A Conference Designed for Actionable ImpactThe conference will feature 350+ speakers across five stages, presenting case studies and panel discussions on AI adoption, assessment redesign, future skills, institutional transformation and digital leadership. Delegates will participate in interactive roundtables and hear real-world strategies from schools and universities across Asia. The EDUtech Asia Awards will celebrate excellence in AI innovation, sustainability, STEAM education and industry collaboration.“EDUtech Asia has always been about driving real change through collaboration and innovation,” said Sophia Ku, Managing Director, EDUtech Asia. “As we celebrate this milestone year, the 2025 edition will be our most significant yet. We’re not just responding to change, but actively leading it. We are bringing together the educators and innovators who are shaping the AI-driven future of learning across Asia, providing them with the knowledge, inspiration and partnerships to unlock the full potential of technology in education.”Asia’s Largest Education Technology ExhibitionRunning alongside the conference, the exhibition will feature over 200 EdTech providers including Google for Education, Lenovo, Samsung, Canvas by Instructure, EdX, AWS and Jamf. Attendees will experience new AI tools and digital platforms through live demonstrations and Start-Up City showcase. The Show & Tell sessions will allow educators to share real classroom case studies and digital transformation success stories. Meanwhile, the 2nd annual Planet Protectors Sustainability Challenge, in partnership with Google for Education, will highlight student-led initiatives tackling environmental issues through innovation and technology.Registration Now OpenPremium conference passes and free exhibition visitor passes are available at: www.terrapinn.com/JoinEDUtechAsia2025ACNEvent Details: EDUtech Asia 20255–6 November 2025Sands Expo & Convention Centre, SingaporeFor more information on EDUtech Asia 2025, please visit: www.terrapinn.com/JoinEDUtechAsia2025ACNAbout Terrapinn  Terrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you’re looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn – spark something  For more information, visit www.terrapinn.com.Press attendance is complimentary. Enquiries should be directed to: Jessica Foong at jessica.foong@terrapinn.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kanagawa and Tokyo, Japan, October 27, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited, Logistics Knight Japan Co., Ltd. (LKJ), and Isuzu Motors Limited, today announced that they will begin a joint pilot project in early November to build a platform for integrated management of pharmaceuticals across the entire logistics network, from manufacturing sites to final delivery destinations such as pharmacies and hospitals. The pilot project will focus on managing transportation quality and temperature control in pharmaceutical logistics. Additionally, it will see the implementation of joint transport and pallet-unit transport simulations aimed at improving logistics efficiency. Figure: Diagram of the pilot projectSpecifically, the project will address three themes: (1) visualization of theoretical inventory values and transport/storage temperatures of pharmaceuticals throughout the entire logistics network in compliance with Japan's Good Distribution Practice (GDP) guidelines for the proper distribution of pharmaceuticals, (2) joint transportation to improve logistics efficiency, and (3) verification of the effectiveness of introducing palletized transport to streamline operations.The initiative aims to tackle some of the challenges currently faced by the logistics industry in Japan such as labor shortages and an aging workforce, leading to reduced transport capacity, increased transportation costs, and extended delivery lead times as well as unnecessary disposal of pharmaceutical products due to supply uncertainties, inventory imbalances, and strict temperature control issues.This pilot project was jointly proposed by LKJ, Isuzu, and Fujitsu, along with TRANSTRON Inc. and Ridgelinez Limited, and was selected as the "Pharmaceutical Logistics Platform Project" under the Ministry of Land, Infrastructure, Transport and Tourism (MLIT)’s publicly solicited "Logistics Innovation Implementation Support Project."Roles of Each Company- LKJ: Provision of specialized knowledge in pharmaceutical logistics.- Isuzu: Provision of a fleet management system to acquire vehicle and operational information during transportation by utilizing the “GATEX” information platform, which delivers advanced management and support services.- Fujitsu: Provision of elemental technologies such as data extraction, transformation, and access control for the logistics and commercial data platform built under the Cabinet Office's Cross-ministerial Strategic Innovation Promotion Program (SIP) Second Phase Smart Logistics Services project, along with the Dynamic Supply Chain Management offering to realize resilient and flexible supply chains.Going forward, LKJ, Isuzu, and Fujitsu will accelerate their efforts toward realizing a pharmaceutical logistics platform by enhancing data collaboration. This will ensure quality across the entire logistics network, reduce inventory waste, and resolve inventory imbalances, thereby contributing to logistics efficiency and stable pharmaceutical supply. The three companies will also collaborate with the Japanese government’s pharmaceutical working group.LKJ aims to solve problems and optimize processes for all pharmaceutical logistics stakeholders (shippers, logistics operators, wholesalers, patients, and customers) from upstream to downstream, by expanding a robust and sustainable stable supply network that can function under any circumstances. It also aims to build a win-win system for the entire pharmaceutical logistics industry.Isuzu will create new services that redefine "transport" for a new era by collaborating with various stakeholders across industries and enhancing the transport and delivery efficiency of carriers and shippers, based on its mid-term management plan "ISUZU Transformation - Growth to 2030 (IX)."Fujitsu, under its Uvance business model, will promote the utilization of logistics data and accelerate inter-industry collaboration to realize resilient supply chains, contributing to a sustainable society and business growth.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, has added three assembly lines in Malaysia with the acquisition of a factory in Penang, establishing its first production foothold outside of China. This move marks a significant step in the Group’s strategic development to diversify its production facilities in Asia and paves the way for further expansion to better meet evolving customer needs.Following the completion of the Group’s acquisition in August this year, Winner Sky Technology Hong Kong Limited and its wholly-owned subsidiary incorporated in Malaysia, Winner Sky Technology Malaysia Sdn. Bhd., (collectively the “Target Group”) have become indirect wholly-owned subsidiaries of Alltronics. This is the first time the Group has wholly-owned subsidiaries with production facilities outside of China. Originally a subcontractor of the Group, the Target Group operates a factory in Penang, Malaysia, and its principal business activities are the manufacturing, assembly and sale of electronic products, components and parts.  To further strengthen its production capabilities, the Group plans to establish a second factory in Malaysia by early next year. The new facility is expected to comprise 12 assembly lines, more than quadrupling the Group's total workforce in Malaysia and substantially increasing its production capacity.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “In the face of today’s dynamic global landscape, we are steadfast in executing our strategy to diversify our production footprint across Asia, which is essential for enhancing our operational resilience and agility. Establishing our first production facility outside China in Malaysia is a pivotal milestone in realizing our strategic vision. This foundation enables us to serve our customers more effectively and create greater long-term value for our shareholders.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “We are focused on seamlessly integrating this new facility into our operations and optimizing its management efficiency. It signifies the beginning of a new chapter of development for Alltronics, and is the cornerstone of our broader ambition to expand our production base in Malaysia and extend to other Asian markets.”About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Jakarta, Indonesia, October 14, 2025 - (ACN Newswire via SeaPRwire.com) - The Archipelago Video Summit, held on 9 October in Jakarta, brought together over 150 senior executives from across Asia to explore the future of video in some of the world’s most dynamic markets of Indonesia, Malaysia and the Philippines.In the opening keynote, Hermawan Sutanto, Managing Director of Vidio, shared how the platform is building a local streaming powerhouse around sports rights and original content to leverage a dual advertising and subscription revenue strategy. Sutanto emphasized that in Indonesia, “execution is everything” while also highlighting Vidio’s aggressive stance against piracy. He also outlined the use of AI in three key areas—hypertargeting user recommendations to drive subscriptions, process automation including customer service, and business innovation such as dynamic ad placement in live sports and local language translation for regional dialects. Looking ahead, he projected that the penetration of OTT streaming in Indonesia could double to 15% within the next five years.In Reinventing for a Dynamic Future, Jane Jimenez-Basas, President & CEO of MediaQuest Holdings and Cignal TV, highlighted the Philippines’ unique media ecosystem and her vision to build a content-focused platform integrated with telco services. While linear TV continues to hold its ground, the real momentum is coming from streaming. However, with lower ARPU, strategic partnerships—such as device distribution and app launches—are essential to scaling reach and driving sustainable growth. “I’m trying to build a content focused ecosystem not a channel business,” said Jimenez-Basas. And with the success Cignal has had with micro-dramas particularly with younger audiences, Jimenez-Basas also revealed their ambition to produce AI-generated micro-dramas in the future.Piracy remained a central theme throughout the summit. Gina Golda Pangaila, SVP, Legal, Anti-Piracy & Government Relation, Vidio, emphasized the need for a multi-layered, industry-wide approach, combining defensive measures like DRM and content protection with offensive strategies that enhance the consumer experience and investing in anti-piracy technologies. She also highlighted the critical role of AVIA and AVISI in lobbying governments to support these efforts. Darmawan Zaini, Chief Technology Officer, Vision+, also called for stronger consumer education—especially among younger audiences—and even suggested exploring penalties for those who consume pirated content. Ian Franklyn, Chief Revenue Officer, MainStreaming, echoed the urgency, and stressed the importance of real-time detection and rapid response especially for live content where pirates profit most and content owners face the greatest losses. “Piracy is no longer a nuisance—it’s organized crime. . .The goal is to give back power to the content owner,” said Franklyn.On the future of satellite video, technology leaders from AsiaSat, MEASAT, and INTEGRASYS reaffirmed satellite’s relevance and cost effectiveness in reaching rural and underserved markets and playing a critical role in bridging the digital divide across Southeast Asia’s archipelagic geographies.In the sessions focused on monetization strategies, speakers acknowledged that while Connected TV (CTV) adoption in Southeast Asia faces infrastructural and content acquisition challenges, its growth trajectory is accelerating rapidly. Tushar Tyagi, Head of Channel Partnerships, Samsung Ads, noted that the region is poised to leapfrog traditional development stages and move directly toward smart, data-driven outcomes, making education, standardization, and AI-powered addressability essential to unlocking CTV’s full monetization potential. The sessions also explored co-viewing trends and the power of contextual advertising, emphasizing the growing importance of data-driven personalization, with innovations in ad formats and audience segmentation helping to drive engagement across both linear and OTT platforms. Sachidananda Panda, President, Client, WPP Media, summed up the future of streaming with the “three I’s”—Intelligence, Integration, and Impact—underscoring the role of AI, cross-platform strategies, and effectiveness in shaping the next wave of video advertising.The CEO Dialogue wrapped up the day with Mike Kerr, Managing Director, Asia, beIN Media Group, emphasizing the importance of disciplined content acquisition and strategic partnerships, particularly in sports, while cautioning against overreliance on traditional advertising models. Alexandre Muller, Managing Director APAC, TV5MONDE noted that Asia’s rapid adoption of new technologies continues to inspire innovation, but success requires deep local understanding and collaboration. The dialogue closed with a shared optimism for the region’s future, grounded in adaptability, innovation, and a commitment to building scalable, consumer-centric media ecosystems.Archipelago Video Summit is proudly sponsored by Gold Sponsors Publica by IAS, Vidio and Vision+ and Silver Sponsors AsiaSat, INTEGRASYS, INVIDI, Magnite, MainStreaming and TV5MONDE.About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.For media enquiries and additional background information, please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.org | Website: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoia |X: @AsiaVideoIA  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Adds Three New Scheduled Flights Weekly For Its Perth-Bali Route- In less than eight months, PT TransNusa Aviation Mandiri strengthens market presence in the Australia-Indonesia market sector by operating 17 scheduled flights weekly- TransNusa positions itself as the best airline connecting Perth and China with under a 2-hour transit duration via Bali- TransNusa fortifies Bali as its international hubJAKARTA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Three-year old TransNusa, ends the third quarter of this year by achieving a historic milestone in growing its Perth-Bali route. In less than eight months after its inaugural flight, TransNusa has increased its flight frequency to 17 scheduled flights weekly.The airline started operating scheduled flights between Perth and Bali on March 20, this year, with just three scheduled flights weekly. TransNusa gradually increased its flight frequency from April through July. By the end of July, this year, TransNusa was already operating 14 scheduled flights weekly. With the latest expansion, the airline will now operate 17 scheduled flights weekly, setting a new benchmark for growth on this popular route.TransNusa Group Chief Executive Officer, Datuk Bernard Francis, who is also a turnaround specialist in the aviation industry, said “This is a legacy moment for TransNusa as we have grown the Perth-Bali route to operate 17 scheduled flights weekly in less than eight months of operating the route, showcasing our strength, confidence and knowledge.”The aviation veteran explained that the momentous achievement was in line with TransNusa’s international growth strategy and aspirations.“By increasing the scheduled flight frequency for the Perth-Bali route, TransNusa now offers passengers the most connectivity options between Western Australia and Indonesia, China as well as Singapore,” said Datuk Bernard, adding that the ticket sales for the new scheduled flights started on October 23.Datuk Bernard explained that the frequency increase is also part of its international expansion strategy in supporting the demand for regional connectivity.“In addition to providing passengers with various connectivity options between Perth and Bali, TransNusa’s passengers from Perth can also enjoy the shortest transit duration, of under two hours, to Guangzhou, China via Bali,” Datuk Bernard said, adding that passengers can also fly to Changi, Singapore, via Bali.DATUK BERNARD FRANCIS… Leading TransNusa to greater heightsDetails Of The Additional Scheduled FlightsTransNusa’s additional three flights, which will be scheduled for Wednesday, Thursday, and Sunday, will start on December 3, 2025.The additional scheduled flight, 8B 084 (DPS-PER), will depart at 00.20am from the I Gusti Ngurah Rai International Airport and arrive at Perth Airport at 04.05am from December 3 onwards. While TransNusa flight, 8B 085 (PER-DPS), will depart Perth Airport at 04.55am and arrived at the I Gusti Ngurah Rai International Airport at 08.45am.TransNusa will continue to operate its current daily scheduled flights, 8B 080 and 8B 082 (DPS-PER), which departs Bali at 09.10am and 12.55pm from I Gusti Ngurah Rai International Airport and arrive the Perth Airport at 12.50pm and 16.55pm. The TransNusa flight, 8B 081 and 8B 083 (PER-DPS), will depart Perth Airport at 13.35pm and 18.05pm, respectively, and arrive at I Gusti Ngurah Rai International Airport in Bali on 17.20pm and 21.50pm.Sale of tickets for the scheduled flight from Perth to Bali will be priced from AUD149 onwards, IDR1.599.000 onwards, CNY565 onwards, and USD84 onwards. Potential passengers can purchase the tickets at transnusa.co.id or any secure Online Travel Agents (OTAs). For passengers who purchase tickets from OTAs, they can check-in at transnusa.co.id.Aiming to offer a comfortable experience to its passenger, TransNusa will be utilising its Airbus A320 that has been configured with only 174 seats, which offers a 30-inch legroom, for this international route that has a 3-hour and 40 minutes flight duration.On TransNusa’s Premium Service Carrier product offerings, Datuk Bernard stressed that for its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refunds, when needed."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” concluded Datuk Bernard.Media Contact:Trina Thomas RajE-mail: trina@myqaseh.org Mobile: +60124992672 (WhatsApp) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Saudi Arabia, Oct 27, 2025 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan’s only international payment brand, and STC Bank has entered into a Memorandum of Understanding (MOU) to start discussion the activation of JCB payment acceptance in Kingdom of Saudi Arabia.As part of supporting the cashless society and financial inclusion aligned with Vision 2030, JCB has initiated discussions with STC Bank to explore a potential partnership aimed at expanding card acceptance in the Kingdom.The MOU sets the framework for both organizations to engage in discussions and assess opportunities to develop acceptance and deliver seamless payment experiences for JCB customers across the Kingdom.Mr. Mohammad Yahya Refaie, Senior Director - Business Banking of STC Bank, said:“Discussion toward building a relationship with JCB will allow STC Bank to support JCB Card acceptance broadly in the Kingdom, facilitate cross-border payments and offer special benefits for JCB cardmembers, such as rewards and promos. It also enhances STC Bank’s international payments capability and enables our merchants to accept JCB payments strengthens its attractiveness to travelers, expatriates, and international merchants, and builds connections into the Asian payment ecosystem”.Takumi Takahashi, Executive Vice president of JCBI, commented:“We are excited to begin discussions with STC Bank, a leading digital bank and are pleased to have the opportunity to build a relationship with a subsidiary of STC Group, the largest telecommunications company in the Kingdom. This MOU marks the first step toward a potential partnership that could transform the way JCB customers access and use financial services in the Kingdom.”About STC BankSTC Bank is Saudi Arabia’s largest fully digital bank, established to empower individuals and businesses with innovative financial services and to contribute to the Kingdom’s Vision 2030. STC Bank continues to lead in digital banking, customer experience, and financial technology, reinforcing its mission to deliver simplicity, trust, and an easy-to-use digital banking experience for all its customers.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 56 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 169 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp　 Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., October 27, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for humanized anti-soluble aggregated amyloidbeta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology. LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with AD. LEQEMBI is also approved in 51 countries and regions including Japan,1 the United States,2 Europe,3 China,4 South Korea,5 Taiwan,6 and SaudiArabia,7 and applications have been filed in 9 countries.The approval of LEQEMBI is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.8,9 LEQEMBI has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Eisai plans to submit clinical assessment data captured from participants in real-world clinical practice.AD is the most common form of dementia, accounting for 60 to 80% of all cases.10 As of January 1,2025, it is estimated there are more than 771,000 patients with dementia in Canada, which is expected to increase to approximately 1 million in 2030 and over 1.7 million in 2050.11 In addition, annual care provided by family and friends for those with dementia is equivalent to 290,000 full-time jobs, which is expected to increase to 690,000 full-time jobs in 2050.11Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision making authority. In Canada, Eisai Limited will distribute the product and conduct information provision activities. Eisai and Biogen are committed to working together with healthcare professionals and other stakeholders towards the early treatment of AD.* Apolipoprotein E is a protein involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous).12** Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.13 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.14MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+1-781-464-2442IR@biogen.comAbout lecanemab (generic name, brand name: LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI’s approvals in these countries was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.8,9 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDRSB score at baseline was approximately 3.2 in both groups. The adjusted least-squares meanchange from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference,−0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment(ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the LEQEMBI group and −5.5in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the LEQEMBI group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.LEQEMBI is approved in 51 countries and regions including Japan,1 the United States,2 Europe,3 China,4 South Korea,5 Taiwan,6 and SaudiArabia,7 and applications have been filed in 9 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in the U.S. and China, and others, and applications have been filed in 5 countries and regions.LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB).8,12 The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In September 2025, the rolling sBLA application to the U.S. FDA for the subcutaneous initiation dosing with LEQEMBI IQLIK was also initiated.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufactureand market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases(NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co.,Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with uson X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202574pdf.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (HKTDC) will hold its 13th Think Business, Think Hong Kong (TBTHK) mega promotion campaign at Palazzo Mezzanotte in Milan on 27 November. This also marks the event’s return to Italy since 2014.Amid the rapidly evolving global landscape and driven by new growth markets – such as the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) and Association of Southeast Asian Nations (ASEAN) – as well as opportunities from the Northern Metropolis initiative in Hong Kong, the event offers Italian businesses an opportunity to explore new markets, build partnerships and foster collaboration across Asia.After successful Paris and Jakarta editions, TBTHK Milan will bring together some 80 representatives from Hong Kong, including government officials, top business leaders, innovators, investors and start-up entrepreneurs, for a day of dialogue, networking and partnership-building with Italian companies keen to expand into Asia.At the event, Prof Frederick Ma, HKTDC Chairman, representatives from the Hong Kong SAR Government and Italian government will deliver remarks. High-profile speakers from various industries will share their insights at the Plenary Session, including Hans Michael Jebsen, Chairman of The Hong Kong-Europe Business Council and Jebsen Group; Bernard Chan, Chairman of West Kowloon Cultural District Authority; Bonnie Chan, CEO of Hong Kong Exchanges and Clearing Limited; Claudio de Bedin, Partner of Justin Chow & de Bedin Solicitors LLP; and Alex Zhavoronkov, Founder and CEO of Insilico Medicine.The programme also includes four thematic sessions, each focusing on a strategic area that reflects shared priorities between Hong Kong and Italy and offers in-depth insights into practical collaboration opportunities:Finance and Trade: Highlighting global economic trends, Hong Kong’s role as a trade hub, its advanced digital trade initiatives, success stories using new technologies and plans to build trade corridors linking Italy, Hong Kong, and the Chinese MainlandInnovation and Technology: Exploring AI developments, greentech, industrial digitalisation and smart city solutions, featuring case studies and testimonials that showcase promising sectors for Italian businesses seeking to expand in AsiaSupply Chain Service: Highlighting the strategic role of corporate treasury centres in strengthening supply chain functions to support Italian business growth and partnerships within Asia’s dynamic market environmentCreative and Design: Focusing on promoting collaboration between Hong Kong and Italian design, lifestyle and manufacturing excellence across Asian markets as well as fashion, art and luxury – areas in which Italian creativity and Asia’s cultural vibrancy intertwineStrong Italy-Hong Kong tiesItaly is an important trading and investment partner of Hong Kong. In 2024, trade between Italy and Hong Kong amounted to US$8.3 billion. This positions Italy as Hong Kong’s fourth-largest trading partner, export market and third-largest import market in the EU.Italy was also the third-largest EU investor in Hong Kong at the end of 2023, while Hong Kong was the third most popular destination for Italian investment in Asia. Hong Kong investors also made substantial investments in Italy, with the city being the third-largest Asian investor in the country. As of 2024, there were 200 Italian companies operating in Hong Kong.The most dynamic sectors include fashion and luxury goods, electronics, food and beverage as well as high-value professional services industries, for which Italian excellence is globally recognised.The Asian metropolis offers a unique global ecosystem, combining competitive taxation, a robust legal framework based on the common law, strong IP protection and privileged access to the Chinese Mainland and emerging Asia-Pacific markets.This combination makes Hong Kong an ideal platform for Italian companies eager to expand internationally, diversify and strengthen their presence in one of the world’s most vibrant regions.A media briefing about TBTHK was held in Milan on 16 October, during which Chris Lo, HKTDC Regional Director for Europe, said: “Hong Kong continues to stand out as a dynamic, international and forward-looking ecosystem. With legal certainty, tax efficiency and direct access to the Chinese Mainland market, the city serves as an ideal bridge for Italian companies seeking to operate in Asia. At the same time, the city represents a major opportunity for Asian companies looking to Europe – and particularly to Italy – as a prime destination for investment, innovation and industrial partnerships.”Gianluca Mirante, HKTDC Director for Italy, added: “Think Business, Think Hong Kong is much more than an event. The campaign accelerates strategic connections between two complementary economies. Italian companies will find in Hong Kong a reliable partner for innovation, growth and international expansion. The initiative serves as a meeting point for institutions, businesses and investors, fostering collaboration and best practices in key areas, such as innovation, finance and sustainable development. It is a concrete opportunity to strengthen ties and open new avenues of cooperation between Italy and Hong Kong.”For more information, please visit TBTHK, Milan’s official website:https://thinkbusinessthinkhk.com/2025-milan/symposium/en/index.htmlRegister for the event on 27 November:https://milan.hktdc.com/index.phpPhoto download: https://bit.ly/3JniDh9   A media briefing was held in Milan on 16 October, during which Chris Lo, HKTDC Regional Director for Europe, announced details of the Think Business, Think Hong Kong mega promotion, to take place in Milan on 27 November(from left) Chris Lo, HKTDC Regional Director for Europe and Gianluca Mirante, HKTDC Director for Italy, attended the Think Business, Think Hong Kong media briefing at Excelsior Hotel Gallia on 16 OctoberThink Business, Think Hong Kong was successfully held in early January in Jakarta, Indonesia. The symposium attracted some 2,000 Indonesian political and business leaders, fostering bilateral trade and investment between Hong Kong and Indonesia. The next edition of the flagship promotional event will take place in Milan, Italy, on 27 November this yearMedia enquiriesHKTDC’s Communication & Public Affairs Department:Jane CheungTel: +852 2584 4137Email: jane.mh.cheung@hktdc.orgWeber ShandwickNadia LauriaTel: +39 3356962981Email: hkmedia@webershandwickitalia.itMarco PedrazziniTel: +39 3470369222Email: hkmedia@webershandwickitalia.itInes BaraldiTel: +39 3428650498Email: hkmedia@webershandwickitalia.itAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com